دورية أكاديمية
Activation of 5-HT1A Receptors Normalizes the Overexpression of Presynaptic 5-HT1A Receptors and Alleviates Diabetic Neuropathic Pain.
| العنوان: | Activation of 5-HT1A Receptors Normalizes the Overexpression of Presynaptic 5-HT1A Receptors and Alleviates Diabetic Neuropathic Pain. |
|---|---|
| المؤلفون: | Munawar N; Department of Pharmacology and Toxicology, College of Medicine, Kuwait University, Al-Jabriya 046302, Kuwait., Bitar MS; Department of Pharmacology and Toxicology, College of Medicine, Kuwait University, Al-Jabriya 046302, Kuwait., Masocha W; Department of Pharmacology and Therapeutics, College of Pharmacy, Kuwait University, Al-Jabriya 046302, Kuwait. |
| المصدر: | International journal of molecular sciences [Int J Mol Sci] 2023 Sep 20; Vol. 24 (18). Date of Electronic Publication: 2023 Sep 20. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI, [2000- |
| مواضيع طبية MeSH: | Diabetes Mellitus, Type 1*/complications , Diabetes Mellitus, Experimental* , Diabetic Neuropathies*/genetics , Neuralgia*/etiology, Animals ; Rats ; Hyperalgesia/etiology ; Tryptophan ; 8-Hydroxy-2-(di-n-propylamino)tetralin ; Hydroxyindoleacetic Acid ; Serotonin ; Tryptophan Oxygenase |
| مستخلص: | Neuropathic pain is a well-documented phenomenon in experimental and clinical diabetes; however, current treatment is unsatisfactory. Serotoninergic-containing neurons are key components of the descending autoinhibitory pathway, and a decrease in their activity may contribute at least in part to diabetic neuropathic pain (DNP). A streptozotocin (STZ)-treated rat was used as a model for type 1 diabetes mellitus (T1DM). Pain transmission was evaluated using well-established nociceptive-based techniques, including the Hargreaves apparatus, cold plate and dynamic plantar aesthesiometer. Using qRT-PCR, Western blotting, immunohistochemistry, and HPLC-based techniques, we also measured in the central nervous system and peripheral nervous system of diabetic animals the expression and localization of 5-HT1A receptors (5-HT1AR), levels of key enzymes involved in the synthesis and degradation of tryptophan and 5-HT, including tryptophan hydroxylase-2 (Tph-2), tryptophan 2,3-dioxygenase (Tdo), indoleamine 2,3-dioxygenase 1 (Ido1) and Ido2. Moreover, spinal concentrations of 5-HT, 5-hydroxyindoleacetic acid (5-HIAA, a metabolite of 5-HT) and quinolinic acid (QA, a metabolite of tryptophan) were also quantified. Diabetic rats developed thermal hyperalgesia and cold/mechanical allodynia, and these behavioral abnormalities appear to be associated with the upregulation in the levels of expression of critical molecules related to the serotoninergic nervous system, including presynaptic 5-HT1AR and the enzymes Tph-2, Tdo, Ido1 and Ido2. Interestingly, the level of postsynaptic 5-HT1AR remains unaltered in STZ-induced T1DM. Chronic treatment of diabetic animals with 8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT), a selective 5-HT1AR agonist, downregulated the upregulation of neuronal presynaptic 5-HT1AR, increased spinal release of 5-HT (↑ 5-HIAA/5-HT) and reduced the concentration of QA, decreased mRNA expression of Tdo , Ido1 and Ido2 , arrested neuronal degeneration and ameliorated pain-related behavior as exemplified by thermal hyperalgesia and cold/mechanical allodynia. These data show that 8-OH-DPAT alleviates DNP and other components of the serotoninergic system, including the ratio of 5-HIAA/5-HT and 5-HT1AR, and could be a useful therapeutic agent for managing DNP. |
| References: | Neurosci Lett. 2004 May 6;361(1-3):229-31. (PMID: 15135935) J Neurosci. 2004 Jun 9;24(23):5420-6. (PMID: 15190115) Arch Pharm Res. 2016 Jan;39(1):59-65. (PMID: 26463700) Ann N Y Acad Sci. 1990;600:384-402; discussion 402-4. (PMID: 2252322) Int J Mol Sci. 2021 Sep 29;22(19):. (PMID: 34638857) J Neuroimmunol. 2009 Sep 29;214(1-2):78-82. (PMID: 19656578) Diabetes. 2002 Mar;51(3):819-24. (PMID: 11872686) J Neurotrauma. 2009 Apr;26(4):575-84. (PMID: 19260781) ScientificWorldJournal. 2013 Dec 08;2013:240508. (PMID: 24385872) Prog Neurobiol. 2002 Apr;66(6):355-474. (PMID: 12034378) J Neural Transm Gen Sect. 1993;91(2-3):135-59. (PMID: 8099796) Eur J Pharmacol. 2010 Dec 15;649(1-3):183-94. (PMID: 20868676) Neurosci Lett. 2016 Apr 21;619:162-7. (PMID: 26987721) Endocrinology. 2010 Dec;151(12):5570-81. (PMID: 21047943) Glia. 2007 Jan 1;55(1):78-92. (PMID: 17024659) J Clin Endocrinol Metab. 2001 Feb;86(2):724-31. (PMID: 11158037) Future Med Chem. 2017 May;9(8):781-795. (PMID: 28504917) Pharmacol Biochem Behav. 2001 Sep;70(1):95-103. (PMID: 11566146) Eur J Pharmacol. 1996 Dec 12;317(1):21-8. (PMID: 8982715) Curr Neuropharmacol. 2019;17(12):1098-1108. (PMID: 31418663) Pain. 1992 Nov;51(2):195-198. (PMID: 1283010) Curr Diab Rep. 2019 Aug 27;19(10):86. (PMID: 31456118) J Biol Chem. 1998 Nov 13;273(46):30239-43. (PMID: 9804782) Behav Brain Res. 2009 Mar 2;198(1):142-8. (PMID: 19046994) Sci Rep. 2021 Jun 4;11(1):11893. (PMID: 34088951) Endocr Rev. 2019 Aug 1;40(4):1092-1107. (PMID: 30901029) Behav Brain Res. 2015 Jan 15;277:136-45. (PMID: 25086269) Brain Res. 1991 Jul 19;554(1-2):56-64. (PMID: 1834306) Pain. 1978 Aug;5(2):135-142. (PMID: 99715) Behav Pharmacol. 2011 Sep;22(5-6):390-404. (PMID: 21808193) Sci Rep. 2020 Oct 1;10(1):16364. (PMID: 33004937) Physiol Res. 2011;60(1):15-25. (PMID: 20945968) Neuropharmacology. 1999 Aug;38(8):1083-152. (PMID: 10462127) J Pharmacol Exp Ther. 1986 Feb;236(2):432-7. (PMID: 2418197) Clin Interv Aging. 2017 Jun 13;12:963-970. (PMID: 28670115) Stem Cells Int. 2021 Nov 8;2021:5212852. (PMID: 34795766) Ann N Y Acad Sci. 2007 Dec;1122:35-49. (PMID: 18077563) Neuropsychopharmacology. 2001 May;24(5):522-30. (PMID: 11282252) J Neurochem. 2008 May;105(4):1346-57. (PMID: 18221377) Physiol Rev. 1992 Jan;72(1):165-229. (PMID: 1731370) Brain Behav Immun. 2015 Nov;50:115-124. (PMID: 26130057) Pharmaceutics. 2022 Oct 10;14(10):. (PMID: 36297581) Pain. 1988 Jan;32(1):77-88. (PMID: 3340425) J Neurochem. 2015 Jul;134(1):135-46. (PMID: 25824528) Neuropsychopharmacology. 2010 Jul;35(8):1734-42. (PMID: 20336058) Pain. 2000 Dec 15;89(1):81-88. (PMID: 11113296) Diabetes. 2003 Sep;52(9):2363-71. (PMID: 12941777) Brain Res Bull. 2003 May 15;60(3):283-96. (PMID: 12754090) Pain. 2014 Apr;155(4):654-662. (PMID: 24291734) Eur J Pharmacol. 1996 Dec 30;318(2-3):315-21. (PMID: 9016920) J Comp Neurol. 2008 Apr 20;507(6):1990-2003. (PMID: 18273889) Biology (Basel). 2020 Aug 24;9(9):. (PMID: 32847122) Clin Endocrinol (Oxf). 2005 Jan;62(1):64-73. (PMID: 15638872) Biochimie. 2019 Jun;161:34-45. (PMID: 31079617) Prog Neurobiol. 2012 Oct;99(1):15-41. (PMID: 22766041) Brain Res. 2009 Jul 14;1280:52-9. (PMID: 19427839) J Comp Neurol. 2001 May 7;433(3):390-400. (PMID: 11298363) J Psychopharmacol. 2000 Jun;14(2):177-85. (PMID: 10890313) J Biol Chem. 2002 Sep 27;277(39):36553-62. (PMID: 12149253) Pharmacol Biochem Behav. 1986 Oct;25(4):883-8. (PMID: 2947249) J Neurochem. 2007 Jul;102(1):103-11. (PMID: 17442055) Psychopharmacology (Berl). 2017 Oct;234(19):2929-2939. (PMID: 28798976) Eur J Pharmacol. 2001 Jun 8;421(2):109-14. (PMID: 11399266) Brain Res. 1999 May 29;830(1):1-9. (PMID: 10350553) Neurochem Res. 1980 Mar;5(3):223-39. (PMID: 6154900) EMBO J. 2011 May 10;30(12):2477-89. (PMID: 21556048) Cell Death Dis. 2011 Oct 13;2:e218. (PMID: 21993394) Eur J Neurosci. 2005 Aug;22(4):895-901. (PMID: 16115212) Dialogues Clin Neurosci. 2002 Jun;4(2):197-210. (PMID: 22033483) J Neurosci. 1992 Feb;12(2):440-53. (PMID: 1531498) Nat Rev Drug Discov. 2019 May;18(5):379-401. (PMID: 30760888) Neurotox Res. 2020 Jun;38(1):50-58. (PMID: 32219734) Rev Diabet Stud. 2015 Spring-Summer;12(1-2):63-83. (PMID: 26676662) Neuropsychopharmacology. 2004 Mar;29(3):461-9. (PMID: 14628002) Brain Res. 1993 Dec 17;631(1):89-96. (PMID: 7507792) Pharmacol Biochem Behav. 2003 Apr;75(1):147-62. (PMID: 12759123) Biosci Rep. 2005 Oct-Dec;25(5-6):363-85. (PMID: 16307382) Cell Signal. 2010 Oct;22(10):1406-12. (PMID: 20363322) J Neurochem. 1984 Dec;43(6):1699-705. (PMID: 6491674) Brain. 1992 Oct;115 ( Pt 5):1249-73. (PMID: 1422788) Mol Brain. 2017 Jun 24;10(1):28. (PMID: 28646910) Br J Pharmacol. 1999 Mar;126(6):1301-6. (PMID: 10217522) Physiol Behav. 1991 Nov;50(5):973-81. (PMID: 1725217) Cells. 2021 Nov 19;10(11):. (PMID: 34831450) J Pain. 2017 Jan;18(1):19-28. (PMID: 27742411) Front Psychiatry. 2017 Aug 14;8:144. (PMID: 28855875) Dis Model Mech. 2017 Mar 1;10(3):215-224. (PMID: 28250049) J Gerontol A Biol Sci Med Sci. 2012 Nov;67(11):1140-52. (PMID: 22451474) |
| معلومات مُعتمدة: | KU: YM05/19 Kuwait University |
| فهرسة مساهمة: | Keywords: 5-HT1A receptor; 8-OH-DPAT; cold allodynia; diabetic neuropathic pain; mechanical allodynia; thermal hyperalgesia |
| المشرفين على المادة: | 8DUH1N11BX (Tryptophan) 78950-78-4 (8-Hydroxy-2-(di-n-propylamino)tetralin) 54-16-0 (Hydroxyindoleacetic Acid) 333DO1RDJY (Serotonin) EC 1.13.11.11 (Tryptophan Oxygenase) |
| تواريخ الأحداث: | Date Created: 20230928 Date Completed: 20230929 Latest Revision: 20231003 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC10532078 |
| DOI: | 10.3390/ijms241814334 |
| PMID: | 37762636 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!